Folfirinox is associated with a long-term survival benefit compared to gemcitabine-abraxane for neoadjuvant therapy before pancreatic cancer surgery

Gage, Michele M.; Wang, P.; Overton, Heidi N.; Sham, Jonathan G.; Javed, Ammar A.; Burkhart, Richard A.; He, Jing; Weiss, Matt; Cameron, John L.; Wolfgang, C.; Makary, Mina

doi:10.1016/j.hpb.2019.03.139

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) and gemcitabine plus nab-paclitaxel (GA) are suggested by clinical practice guidelines as first-line therapies for patients with BRPC and LAPC, given data from two phase III clinical trials that demonstrated longer overall survival in metastatic PC patients treated with either FOLFIRINOX or GA than in those treated with gemcitabine alone (13,14). Currently, although several studies have compared the efficacy of FOLFIRINOX and GA in localized PC, no consensus has been reached (15)(16)(17)(18)(19)(20)(21)(22).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Head-to-head comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel in the neoadjuvant chemotherapy of localized pancreatic cancer: a systematic review and meta-analysis

Tang¹,

Meng²,

Wang³

et al. 2021

Gland Surg

View full text Add to dashboard Cite

Background: The benefits of neoadjuvant chemotherapy (NCT) in pancreatic cancer (PC) have been realized and gradually accepted. FOLFIRINOX and gemcitabine and nab-paclitaxel (GA) are the two most widely used regimens for PC NCT. Methods:The literature was systematically reviewed by searching MEDLINE, EMBASE, Web of Science and the Cochrane Library for studies published until September 2020.Results: Eight studies were eligible for the meta-analysis. Compared to GA, neoadjuvant FOLFIRINOX significantly prolonged overall survival [hazard ratio (HR) =0.65, 95% confidence interval (95% CI): 0.55-0.77; P<0.001]. FOLFIRINOX provided better survival benefits in the first three years after surgery; however, the 4-and 5-year survival probabilities of the two strategies were similar based on a conservative estimation in the random effect model. The perioperative parameters analysed included perineural invasion (PNI), lymphovascular invasion (LVSI), R0 status, postoperative complications and resection rate. The PNI rate was marginally elevated in the GA group compared with the FOLFIRINOX cohort [79.8% vs. 70.5%, odds ratio (OR) =0.70, 95% CI: 0.47-1.06, P=0.09], which may account for the potential survival benefits of FOLFIRINOX. Conclusions:The results of our meta-analysis suggest that FOLFIRINOX is non-inferior to GA in patients who are FOLFIRINOCX capable.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Some studies reported that FOLFIRINOX prolongs survival more than GA (19,21,22), while others showed that the efficacy of these two regimens is similar (16)(17)(18)20,23).…”

Section: Introductionmentioning

confidence: 99%

Head-to-head comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel in the neoadjuvant chemotherapy of localized pancreatic cancer: a systematic review and meta-analysis

Tang¹,

Meng²,

Wang³

et al. 2021

Gland Surg

View full text Add to dashboard Cite

show abstract

Folfirinox is associated with a long-term survival benefit compared to gemcitabine-abraxane for neoadjuvant therapy before pancreatic cancer surgery

Abstract: Background: Peri-operative pain management around the time of hepato-pancreatic (HP) surgery has been debated.

Cited by 1 publication

References 0 publications

Head-to-head comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel in the neoadjuvant chemotherapy of localized pancreatic cancer: a systematic review and meta-analysis

Head-to-head comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel in the neoadjuvant chemotherapy of localized pancreatic cancer: a systematic review and meta-analysis

Contact Info

Product

Resources

About